PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024

Market: Pharmaceuticals and Healthcare

Global, 409 pages report, published by GlobalData

Report ThumbnailDecember-2015
PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024

Summary

Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved a

Read More
  • 1.2 List of Figures
  • Figure 1: 8MM, Age-Adjusted Gastric Cancer Incidence (Cases per 100,000 Population), Men, 1998-2007 40
  • Figure 2: 8MM, Age-Adjusted Gastric Cancer Incidence (Cases per 100,000 Population), Women, 1998-2007 40
  • Figure 3: 8MM, Diagnosed Incident Cases of Gastric Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024 65
  • Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Both Sexes, N, 2014 67
  • Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Ag
Read More
  • 1.1 List of Tables
  • Table 1: Stage Definitions for Gastric Cancer 32
  • Table 2: Symptoms of Gastric Cancer 33
  • Table 3: Prognosis of Gastric Cancer in the US and UK 34
  • Table 4: Risk Factors and Comorbidities for Gastric Cancer 38
  • Table 5: 8MM, Sources of Gastric Cancer Incidence Data 42
  • Table 6: 8MM, Sources Used in the Epidemiology Forecast for the Five-Year Diagnosed Prevalent Cases of Gastric Cancer 43
  • Table 7: 8MM, Sources of Gastric Cancer Stage at Diagnosis According to AJCC, TNM (Tumor, Node,
Read More
  • 1 Table of Contents
  • 1 Table of Contents 10
  • 1.1 List of Tables 17
  • 1.2 List of Figures 23
  • 2 Introduction 26
  • 2.1 Catalyst 26
  • 2.2 Related Reports 27
  • 2.3 Upcoming Related Reports 27
  • 3 Disease Overview 28
  • 3.1 Etiology and Pathophysiology 28
  • 3.1.1 Etiology 28
  • 3.1.2 Pathophysiology 28
  • 3.1.3 Biomarkers/Targets of Interest 30
  • 3.2 Staging 31
  • 3.3 Symptoms 33
  • 3.4 Prognosis 33
  • 3.5 Quality of Life 34
  • 4 Epidemiology 36
  • 4.1 Disease Background 36
  • 4.2 Risk Factors and Comorbidities 37
  • 4.3 Global Trends 38
  • 4.3.1 8M
Read More
  • Gastric Cancer Treatment Market Will Expand Rapidly towards $4.4 Billion by 2024, says GlobalData

    The treatment market for gastric and gastroesophageal junction adenocarcinoma (gastric cancer) will experience rapid growth, from $1.13 billion in 2014 to reach $4.39 billion by 2024, representing an impressive Compound Annual Growth Rate (CAGR) of 14.6%, according to research and consulting firm GlobalData.

    The company’s latest report* states that this rise, which will occur across the eight Maj
Read More

Please select a license type

Share

Related Products

GlobalDataPharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024Product ThumbnailPharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024, Industry ReportProduct #: 413527
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2021 Global Market Analyst. All Rights Reserved